Takeda Pharmaceuticals International Gmbh Glattpark Ch Email Formats

General Wholesale • Glattpark, Zurich, Switzerland • 51-100 Employees

Takeda Pharmaceuticals International Gmbh Glattpark Ch Email Formats

Takeda Pharmaceuticals International Gmbh Glattpark Ch uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@takeda.com), used 72.2% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@takeda.com	72.2%
{first initial}.{last name}	j.doe@takeda.com	27.8%

Key Contacts at Takeda Pharmaceuticals International Gmbh Glattpark Ch

Jochen Titze

Senior Director - Procurement Lead Direct Materials Raw & Pack & Japan Gms Procurement Lead

Eugene Osei-Bonsu

Senior Director - Neuroscience Marketing And Strategy Lead - Global Portfolio Division

Beatrice P. Pimlac

Operational Excellence Deployment Lead Assoc. Director

Eve Huber

Director Strategy & Marketing Neuroscience, Global Portfolio Division

Hugo Souren

Senior Director Head Of Eucan & Gem Tax

Amaury Wilmet

Managed Access Program/ Patient Access - Npp & Capability Building Strategy, Director

Birgit Lughofer-Leibnitz

Portfolio And Business Excellence Lead, Director

Wahida Tabet Aoul

Director Medical Communications Vaccine

Paola Agrigento

Associate Director Regulatory Affairs Vaccines Europe

Lisa Barkei

Associate Director Supply Chain Systems & Master Data Lead Eu

Company overview

Headquarters	THURGAUERSTRASSE 130, Ch-8152 Glattpark (Opfikon), ch
Website	takeda.com
NAICS	42
Employees	51-100
Socials

About Takeda Pharmaceuticals International Gmbh Glattpark Ch

TAKEDA PHARMACEUTICALS INTERNATIONAL GMBH GLATTPARK CH is a wholesale company based out of THURGAUERSTRASSE 130, Ch-8152 Glattpark (Opfikon), Switzerland. The double-blind, randomized, placebo-controlled Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial is evaluating the safety and efficacy of two doses of TAK-003 in the prevention of laboratory-confirmed symptomatic dengue fever of any severity and due to any of the four dengue virus serotypes in children and adolescents.8 Study participants were randomized 2:1 to receive two doses of TAK-003 0.5 mL or placebo on Months 0 and 3, administered subcutaneously.8 The study is comprised of five parts. Part 1 and the primary endpoint analysis evaluated vaccine efficacy (VE) and safety through 12 months after the second dose.8 Part 2 continued for an additional six months to complete the assessment of the secondary endpoints of VE by serotype, baseline serostatus and disease severity, including VE against hospitalized dengue.8 Part 3 evaluated VE and long-term safety by following participants for an additional two and a half to three years, as per World Health Organization (WHO) recommendations.11 Part 4 will evaluate efficacy and safety for 13 months following booster vaccination, and Part 5 will evaluate long-term efficacy and safety for one year after completion of Part

Employees by Management Level

Total employees: 51-100

Seniority

Employees

Manager

Director

Entry

Employees by Department

Takeda Pharmaceuticals International Gmbh Glattpark Ch has 52 employees across 8 departments.

Departments

Number of employees

Funding Data

Takeda Pharmaceuticals International Gmbh Glattpark Ch has never raised funding before.

Frequently asked questions

Takeda Pharmaceuticals International Gmbh Glattpark Ch is located in Glattpark, Zurich, CH.

Takeda Pharmaceuticals International Gmbh Glattpark Ch has approximately 51-100 employees. The company continues to grow its workforce to support its business operations and expansion.